Huang et al. noted that the miR-223/PAX6 axis promoted disease progression and drug resistance by the activation of the PI3K/Akt signaling pathway, suggesting the possible use of this pathway as a novel potential therapeutic intervention for glioblastoma [43]. This evidence concerns the gene PAX6 and glioblastoma.